Amazon Explores AI Content Marketplace With Media Publishers 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
TUCSON, Ariz., Dec. 20, 2017 -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.
To schedule a meeting with HTG Molecular, investors can register on the online system managed by the Company’s US investor relations firm, LifeSci Advisors, LLC, or make a request via e-mail at [email protected].
About HTG:
Headquartered in Tucson, Arizona, the mission of HTG is to empower precision medicine at the local level. The company’s HTG EdgeSeq technology, which automates highly multiplexed molecular profiling of small samples for next-generation sequencing, received its first US patent in 2014. Continuous improvements led to the 2017 launch of HTG’s new direct-target sequencing chemistry for DNA analysis offered in the company’s VERI/O services laboratory. Additional information is available at www.htgmolecular.com.
Contact:
LifeSci Advisors, LLC
Ashley Robinson
Phone: (617) 775-5956
Email: [email protected]
TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: (520) 547-2827 x130
Email: [email protected]
